Effects of Granulocyte-colony Stimulating Factor and the Expression of Its Receptor on Various Malignant Cells

Overview

Journal Korean J Hematol

Specialty Hematology

Date 2012 Oct 17

PMID 23071478

Citations 6

Authors

Hee Won Moon

Tae Young Kim

Bo Ra Oh

Sang Mee Hwang

Jiseok Kwon

Ja-Lok Ku

Dong Soon Lee

Affiliations

Soon will be listed here.

Abstract

Background: Granulocyte-colony stimulating factor (G-CSF) is extensively used to improve neutrophil count during anti-cancer chemotherapy. We investigated the effects of G-CSF on several leukemic cell lines and screened for the expression of the G-CSF receptor (G-CSFR) in various malignant cells.

Methods: We examined the effects of the most commonly used commercial forms of G-CSF (glycosylated lenograstim and nonglycosylated filgrastim) on various leukemic cell lines by flow cytometry. Moreover, we screened for the expression of G-CSFR mRNA in 38 solid tumor cell lines by using real-time PCR.

Results: G-CSF stimulated proliferation (40-80% increase in proliferation in treated cells as compared to that in control cells) in 3 leukemic cell lines and induced differentiation of AML1/ETO+ leukemic cells. Among the 38 solid tumor cell lines, 5 cell lines (hepatoblastoma, 2 breast carcinoma, squamous cell carcinoma of the larynx, and melanoma cell lines) showed G-CSFR mRNA expression.

Conclusion: The results of the present study show that therapeutic G-CSF might stimulate the proliferation and differentiation of malignant cells with G-CSFR expression, suggesting that prescreening for G-CSFR expression in primary tumor cells may be necessary before using G-CSF for treatment.

Citing Articles

G-CSF/GM-CSF-induced hematopoietic dysregulation in the progression of solid tumors.

He K, Liu X, Hoffman R, Shi R, Lv G, Gao J FEBS Open Bio. 2022; 12(7):1268-1285.

PMID: 35612789 PMC: 9249339. DOI: 10.1002/2211-5463.13445.

Paraneoplastic hyperleucocytosis in a melanoma patient after initiation of ipilimumab and nivolumab combination therapy.

Gambichler T, Stockfleth E, Susok L J Immunother Cancer. 2018; 6(1):113.

PMID: 30376886 PMC: 6208032. DOI: 10.1186/s40425-018-0430-y.

The dark side of granulocyte-colony stimulating factor: a supportive therapy with potential to promote tumour progression.

Yeo B, Redfern A, Mouchemore K, Hamilton J, Anderson R Clin Exp Metastasis. 2018; 35(4):255-267.

PMID: 29968171 DOI: 10.1007/s10585-018-9917-7.

Highly Expressed Granulocyte Colony-Stimulating Factor (G-CSF) and Granulocyte Colony-Stimulating Factor Receptor (G-CSFR) in Human Gastric Cancer Leads to Poor Survival.

Fan Z, Li Y, Zhao Q, Fan L, Tan B, Zuo J Med Sci Monit. 2018; 24:1701-1711.

PMID: 29567938 PMC: 5880331. DOI: 10.12659/msm.909128.

Recombinant Human Granulocyte Colony-Stimulating Factor Promotes Preinvasive and Invasive Estrogen Receptor-Positive Tumor Development in MMTV-erbB2 Mice.

Zhao C, Zhang G, Xiao Z, Ma Z, Lei C, Song S J Breast Cancer. 2015; 18(2):126-33.

PMID: 26155288 PMC: 4490261. DOI: 10.4048/jbc.2015.18.2.126.

References

Kroger N, Sonnenberg S, Cortes-Dericks L, Freiberger P, Mollnau H, Zander A . Kinetics of G-CSF and CD34+ cell mobilization after once or twice daily stimulation with rHu granulocyte-stimulating factor (lenograstim) in healthy volunteers: an intraindividual crossover study. Transfusion. 2003; 44(1):104-10. DOI: 10.1111/j.0041-1132.2004.00618.x. View

Park H, Yang J, Chung K . Characterization of the cytokine profile of platelet rich plasma (PRP) and PRP-induced cell proliferation and migration: Upregulation of matrix metalloproteinase-1 and -9 in HaCaT cells. Korean J Hematol. 2012; 46(4):265-73. PMC: 3259519. DOI: 10.5045/kjh.2011.46.4.265. View

Morales-Arias J, Meyers P, Bolontrade M, Rodriguez N, Zhou Z, Reddy K . Expression of granulocyte-colony-stimulating factor and its receptor in human Ewing sarcoma cells and patient tumor specimens: potential consequences of granulocyte-colony-stimulating factor administration. Cancer. 2007; 110(7):1568-77. DOI: 10.1002/cncr.22964. View

Godwin J, Kopecky K, Head D, Willman C, Leith C, HYNES H . A double-blind placebo-controlled trial of granulocyte colony-stimulating factor in elderly patients with previously untreated acute myeloid leukemia: a Southwest oncology group study (9031). Blood. 1998; 91(10):3607-15. View

Ohno R, Tomonaga M, Kobayashi T, Kanamaru A, Shirakawa S, Masaoka T . Effect of granulocyte colony-stimulating factor after intensive induction therapy in relapsed or refractory acute leukemia. N Engl J Med. 1990; 323(13):871-7. DOI: 10.1056/NEJM199009273231304. View

Shimizu K, Kitabayashi I, Kamada N, Abe T, Maseki N, Suzukawa K . AML1-MTG8 leukemic protein induces the expression of granulocyte colony-stimulating factor (G-CSF) receptor through the up-regulation of CCAAT/enhancer binding protein epsilon. Blood. 2000; 96(1):288-96. View

Hirbe A, Uluckan O, Morgan E, Eagleton M, Prior J, Piwnica-Worms D . Granulocyte colony-stimulating factor enhances bone tumor growth in mice in an osteoclast-dependent manner. Blood. 2006; 109(8):3424-31. PMC: 1852257. DOI: 10.1182/blood-2006-09-048686. View

Takamatsu Y, Miyamoto T, Iwasaki H, Makino S, Tamura K . Remission induction by granulocyte colony-stimulating factor in hypoplastic acute myelogenous leukemia complicated by infection. A case report and review of the literature. Acta Haematol. 1998; 99(4):224-30. DOI: 10.1159/000040844. View

Obermueller E, Vosseler S, Fusenig N, Mueller M . Cooperative autocrine and paracrine functions of granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor in the progression of skin carcinoma cells. Cancer Res. 2004; 64(21):7801-12. DOI: 10.1158/0008-5472.CAN-03-3301. View

10.

Hernandez-Bernal F, Garcia-Garcia I, Gonzalez-Delgado C, Valenzuela-Silva C, Soto-Hernandez R, Duconge J . Bioequivalence of two recombinant granulocyte colony-stimulating factor formulations in healthy male volunteers. Biopharm Drug Dispos. 2005; 26(4):151-9. DOI: 10.1002/bdd.445. View

11.

Tachibana M, Miyakawa A, Nakashima J, Murai M, Nakamura K, Kubo A . Autocrine growth promotion by multiple hematopoietic growth factors in the established renal cell carcinoma line KU-19-20. Cell Tissue Res. 2000; 301(3):353-67. DOI: 10.1007/s004410000235. View

12.

Ferrara F, Di Noto R, Viola A, Russo C, Boccuni P, Costantini S . Complete remission in acute myeloid leukaemia with t(8;21) following treatment with G-CSF: flow cytometric analysis of in vivo and in vitro effects on cell maturation. Br J Haematol. 1999; 106(2):520-3. DOI: 10.1046/j.1365-2141.1999.01580.x. View

13.

Moon H, Shin S, Kim H, Kim Y, Cho H, Yoon S . Therapeutic use of granulocyte-colony stimulating factor could conceal residual malignant cells in patients with AML1/ETO+ acute myelogenous leukemia. Leukemia. 2006; 20(8):1408-13. DOI: 10.1038/sj.leu.2404286. View

14.

Usuki K, Urabe A, Masaoka T, Ohno R, Mizoguchi H, Hamajima N . Efficacy of granulocyte colony-stimulating factor in the treatment of acute myelogenous leukaemia: a multicentre randomized study. Br J Haematol. 2002; 116(1):103-12. DOI: 10.1046/j.1365-2141.2002.03251.x. View

15.

van Lochem E, van der Velden V, Wind H, Te Marvelde J, Westerdaal N, van Dongen J . Immunophenotypic differentiation patterns of normal hematopoiesis in human bone marrow: reference patterns for age-related changes and disease-induced shifts. Cytometry B Clin Cytom. 2004; 60(1):1-13. DOI: 10.1002/cyto.b.20008. View

16.

Da Silva N, Meyer-Monard S, Menot M, Parrado A, Lebel A, Balitrand N . Functional G-CSF pathways in t(8;21) leukemic cells allow for differentiation induction and degradation of AML1-ETO. Hematol J. 2002; 1(5):316-28. DOI: 10.1038/sj.thj.6200047. View

17.

Sung L, Nathan P, Alibhai S, Tomlinson G, Beyene J . Meta-analysis: effect of prophylactic hematopoietic colony-stimulating factors on mortality and outcomes of infection. Ann Intern Med. 2007; 147(6):400-11. DOI: 10.7326/0003-4819-147-6-200709180-00010. View

18.

Savarese T, Mitchell K, McQuain C, Campbell C, Guardiani R, Wuu J . Coexpression of granulocyte colony stimulating factor and its receptor in primary ovarian carcinomas. Cancer Lett. 2000; 162(1):105-15. DOI: 10.1016/s0304-3835(00)00623-6. View

19.

Noda I, Fujieda S, Ohtsubo T, Tsuzuki H, Tanaka N, SUNAGA H . Granulocyte-colony-stimulating factor enhances invasive potential of human head-and-neck-carcinoma cell lines. Int J Cancer. 1999; 80(1):78-84. DOI: 10.1002/(sici)1097-0215(19990105)80:1<78::aid-ijc16>3.0.co;2-s. View

20.

Hernandez-Campo P, Almeida J, Matarraz S, de Santiago M, Sanchez M, Orfao A . Quantitative analysis of the expression of glycosylphosphatidylinositol-anchored proteins during the maturation of different hematopoietic cell compartments of normal bone marrow. Cytometry B Clin Cytom. 2006; 72(1):34-42. DOI: 10.1002/cyto.b.20143. View